XML 48 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Selected Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]    
Accrued compensation [1] $ 2,452 $ 3,556
Cash holdback liability 600
Accrued vendor and other expenses 2,812 1,596
Total accrued expenses and other current liabilities $ 5,264 $ 5,752
[1] Includes approximately $0.9 million in severance accrual as of March 31, 2021, in accordance with the severance benefits provided under certain employment and severance benefit agreements, in connection with Oncocyte's partial reduction in force plan and salary reduction agreements instituted in September 2020 (see Note 14).